J&J Reports Two-Year Icotrokinra Durability Data in Plaque Psoriasis
J&J reports two-year icotrokinra durability data in difficult-to-treat plaque psoriasis, positioning the oral agent as a first-line systemic therapy for dermatologists.
Topic
Topic
J&J reports two-year icotrokinra durability data in difficult-to-treat plaque psoriasis, positioning the oral agent as a first-line systemic therapy for dermatologists.